BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Abbott Laboratories Ltd submitted on 28 March 2002 an application for Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Humira, 
in accordance with the centralised procedure falling within the scope of Part A of the Annex to 
Council Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr Tomas Salmonson Co-Rapporteur: Dr Pasqualino Rossi 
Scientific Advice: 
The applicant received Scientific Advice from the CPMP on 29 July 1999 and 19 October 2000. The 
Scientific Advice pertained to parts II, III and IV of the dossier.  
Licensing status: 
Humira has been given a Marketing Authorisation in the USA on 31 December 2002. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 22 April 2002.  
The Rapporteur's first Assessment Report was circulated to all CPMP members on 3 July 2002. 
The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  3  July 
2002  
During  the  meeting  on  23 –25  July  2002  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 25 July 2002. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  12 
November 2002.  
The  Rapporteur  and  Co-Rapporteur  circulated  the  response  Assessment  Report  on  the 
company’s responses to the List of Questions to all CPMP members on 3 January 2003).  
The summary report of the inspection carried out at the manufacturing site between 18 and 22 
November 2002 of the Abbott Bioresearch Center was issued on 15 January 2003. 
During the CPMP meeting on 21-23 January 2003, the CPMP agreed on the List of Outstanding 
Issues to be sent to the Applicant. 
The company submitted the responses to the List of Outstanding Issues on 12 March 2003. 
The Rapporteurs circulated the response Joint Assessment Report on the company’s responses 
to the List of Outstanding Issues to all CPMP members on 4 April 2003. 
During  the  CPMP  meeting  on  23-25  April  2003,  the  CPMP  agreed  on  an  additional  List  of 
Outstanding Issues to be sent to the Applicant. 
The  company  submitted  the  responses  to  the  additional  List  of  Outstanding  Issues  on 
2 May 2003. 
The Rapporteurs circulated the response Joint Assessment Report on the company’s responses 
to the additional List of Outstanding Issues to all CPMP members on 9 May 2003. 
The company provided on 22 May 2003, a letter of undertaking on the follow-up measures to be 
fulfilled as requested by the CPMP. 
During the meeting on 20-22 May 2003 the CPMP, in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Humira on 22 May 2003. 
1/2 
EMEA 2005 
 
 
• 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 8 September 2003 
2/2 
EMEA 2005 
 
 
 
